presteram
les laboratoires servier - perindoprilio argininas/amlodipinas - tabletės - 10 mg/5 mg; 10 mg/10 mg; 5 mg/10 mg; 5 mg/5 mg - perindopril and amlodipine
presteram
les laboratoires servier - perindoprilio argininas/amlodipinas - tabletės - 10 mg/10 mg - perindopril and amlodipine
roxiper
krka, d.d., novo mesto - rozuvastatinas/tert-butilamino perindoprilis/indapamidas - plėvele dengtos tabletės - 10 mg/4 mg/1,25 mg - rosuvastatin, perindopril and indapamide
roxiper
krka, d.d., novo mesto - rozuvastatinas/tert-butilamino perindoprilis/indapamidas - plėvele dengtos tabletės - 20 mg/4 mg/1,25 mg - rosuvastatin, perindopril and indapamide
roxiper
krka, d.d., novo mesto - rozuvastatinas/tert-butilamino perindoprilis/indapamidas - plėvele dengtos tabletės - 10 mg/8 mg/2,5 mg - rosuvastatin, perindopril and indapamide
roxiper
krka, d.d., novo mesto - rozuvastatinas/tert-butilamino perindoprilis/indapamidas - plėvele dengtos tabletės - 20 mg/8 mg/2,5 mg - rosuvastatin, perindopril and indapamide
tonarssa
krka, d.d., novo mesto - tert-butilamino perindoprilis/amlodipinas - tabletės - 5,7 mg/5 mg; 2,85 mg/2,5 mg - perindopril and amlodipine
perindopril arginine krka
krka, d.d., novo mesto - perindoprilio argininas - tabletės - 5 mg - perindopril
perindopril arginine krka
krka, d.d., novo mesto - perindoprilio argininas - tabletės - 10 mg - perindopril
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.